1. A hemostatic hydrogel composition (100) for rapid and synergistic bleeding
control of a patient comprising:
a first agent (110) configured to induce platelet plug formation;
a second agent (120) to induce vasoconstriction; and
a third agent (130) to activate coagulation cascade in the patient.
2. The hemostatic hydrogel composition (100) as claimed in claim 1, wherein:
the first agent (110) is selected from a cationic polymer, a polysaccharide, a protein, an electrostatic agent, and an amine group containing polymer;
the second agent (120) comprises potassium aluminum sulfate, aluminum ammonium sulfate, aluminum sulfate, and aluminum chloride hydrate, a vasoactive catecholamine, a vasoactive peptide, epinephrine, norepinephrine, levonordefrin, isoproterenol, dopamine, methoxamine, phenylephrine; tyramine, amphetamine, methamphetamine, hydroxyamphytamine, metaraminol, ephedrine and mixtures thereof; and the third agent is selected from calcium chloride (CaCl2), calcium oxide (CaO), calcium hydroxide (Ca(OH)2), calcium nitrate (Ca(NO3)2), calcium carbonate (CaCO3), calcium oxalate (C2H2CaO5), magnesium chloride (MgCl2), magnesium oxide (MgO), magnesium hydroxide (Mg(OH)2), magnesium nitrate (Mg(NO3)2), magnesium carbonate (MgCO3), pigeonite and mixtures thereof.
3. The hemostatic hydrogel composition (100) as claimed in claim 1, comprising:
0.01% to 5 % of chitosan (110) as first agent;
0.01% to 0.5 % of potassium aluminium sulphate (120) as second agent; and 0.01 % to 0.5 % a calcium salt (130) as third agent, wherein the clotting time is in the range of 30s to 140s.

4. The composition as claimed in claim 1, comprising protamine sulfate at a dosage of 0.6mg/kg to 1.3mg/kg weight of the patient.
5. The composition as claimed in claim 1, wherein the said hydrogel is formed into a shape selected from sponge, flexible bandage, scaffold, injectable gel, foam, cream and powder form.
6. The composition as claimed in claim 1, wherein the said composition is stable at a temperature range of 25 to 50 °C.
7. The composition as claimed in claim 1, wherein the said composition exhibits one or more characteristics selected from:
a hemolytic potential of 5 percent or less; a RBC aggregation of 0.2 or more; a platelet aggregation of 0.4 or more; and an adhesion strength of 6-10 kPa.
8. The composition as claimed in claim 1, wherein the chitosan has molecular weight in the range of 25 kDa to 1000 kDa, an average degree of deacetylation between 40% to about 99% and degree of acetylation between 1% to about 70%.
9. The composition as claimed in claim 1, comprising:
2 % of chitosan;
0.25 % of potassium aluminium sulphate; and
0.25 % calcium salt.
10. A method (200) of preparing a hemostatic composition (100), comprising:

adding (202) 0.01% to 5% of chitosan powder in acetic acid under continuous stirring to form a chitosan solution;
adding (204) sodium hydroxide to the chitosan solution under continuous stirring to adjust the pH;
centrifuging (206) the said solution to form a chitosan hydrogel;
mixing (208) 0.01% to 0.5% of potassium aluminium sulphate to chitosan hydrogel under vigorous stirring to form a homogeneous mixture;
adding (210) 0.01% to 0.5% calcium chloride to the homogeneous mixture under vigorous stirring to obtain the homogenous mixture of composite hydrogel.
11. The method as claimed in claim 10, wherein the pH of the chitosan solution is adjusted in the range of 6 to 7.